share_log

Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $18

Moomoo 24/7 ·  Apr 3 11:18

Goldman Sachs analyst Corinne Jenkins maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $16 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment